About ERYtech

ERYtech Pharma creates high value products for hospital market, mainly in hematology and oncology fields.

ERYtech Pharma has a first success with its lead compound Graspa® which demonstrated positive results and excellent safety profile compared to control treatment in Phase II trials in acute lymphoblastic leukaemia. Phase III in leukaemia will start in 2009 and a development program of Graspa® in several other indications notably solid tumors is ongoing.

Headquartered in France with a cGMP manufacturing unit, ERYtech Pharma has a US Office and a US location for cGMP clinical batches production in partnership with the American Red Cross.

ERYtech Pharma’s business & revenue model is both:

  • An integrated business & revenue model for proprietary product to maximize value creation
  • A business development partnership revenue model

 

Main achievements and highlights:

 2010

  • FDA grants Orphan Drug Designation to GRASPA® for treatment of Acute Lymphoblastic Leukaemia

2009

  • Pivotal Clinical Trial for GRASPA® in Acute Lymphoblastic Leukaemia in Europe
  • Phase II Clinical Trial with GRASPA® as first-line treatment among patients with Acute Lymphoblastic Leukaemia aged 55 and older
  • cGMP facility certification from the French Health Products Safety Agency (AFSSAPS)
  • American Red Cross manufacturing and supply agreements
  • ISO 9001:2008 certification
  • Granted by the French Ministry of Research
  • Supervisory Board and Scientific Board reinforced

2008

  • Phase I/II Clinical Trial for GRASPA®: last patient enrolled and results presented at the 50th Annual Meeting of the American Society of Hematology (ASH) in San Francisco
  • Granted by France's National Research Agency and the Lyon Auvergne Rhône-Alpes Cancer Research Cluster (CLARA)

 2007

  • Phase I/II Clinical Trial for GRASPA®: launching in Belgium
  • New Headquarters, R&D laboratory and cGMP facility in Lyon

2006

  • Phase I/II Clinical Trial for GRASPA®: first patient enrolled
  • EMEA awards Medicinal Product classification for GRASPA®
  • EMEA awards Orphan Drug Designation for GRASPA®
  • Financing round A € 12 million

 2005

  • Seed Financing Round € 750.000 with financial shareholders and business angels
  • Granted by the French Ministry of Research, France's National Research Agency, Rhône-Alpes Région and the Lyon Auvergne Rhône-Alpes Cancer Research Cluster (CLARA)

 2004

  • ERYtech Pharma incorporation
  • Granted by the French Ministry of Research and award from the Rhône-Alpes Ouest Créalys business incubator

 

Erytech Pharma
Last Update 04/03/2010
2005 ERYtech Inc. All Rights Reserved | Terms and Conditions | Contact Us